Evaluation of Bone Metabolism Biomarkers in Paget's Disease of Bone
Evaluation of Bone Metabolism Biomarkers in Paget's Disease of Bone
复制标题
DOI：
10.7759/cureus.4791
复制
发表时间：
2019-05-31
影响因子：
1.2
通讯作者：
Frode, Tania S.
中科院分区：
文献类型：
--
作者：
de Castro, Glaucio R. Werner;Buss, Ziliani Da Silva;Frode, Tania S.
目的：评价佩吉特骨病（PDB）患者血清骨代谢生物标志物水平。方法：测定57例骨Paget病患者和24例原发性骨关节炎患者血清骨桥蛋白、硬化蛋白、核因子κ b受体激活剂配体（RANKL）、骨保护素、dickkopf相关蛋白1 （DKK-1）和可溶性卷曲相关蛋白1 （sFRP-1）的水平。采用亚组分析，根据疾病活动度或当前治疗确定骨代谢生物标志物水平的差异。结果：PDB患者骨桥蛋白和RANKL水平升高。与非活动性疾病患者相比，活动性疾病患者的骨特异性碱性磷酸酶（BAP）和骨桥蛋白水平较高。血清BAP水平与骨桥蛋白水平有显著相关性。BAP水平与其他骨代谢生物标志物之间无显著相关性。骨显像显示当前疾病扩展与血清骨桥蛋白和BAP水平有显著相关性。目前疾病扩展与其他骨代谢生物标志物之间没有显著相关性。血清骨桥蛋白和RANKL水平与血清BAP水平和疾病扩展相关。结论：PDB患者骨桥蛋白和RANKL水平升高。骨桥蛋白可作为PDB活性和延伸的有用生物标志物。
Objective: To evaluate serum levels of bone metabolism biomarkers in patients with Paget's disease of bone (PDB).Methods: Serum levels of osteopontin, sclerostin, receptor activator of nuclear factor kappa-B ligand (RANKL), osteoprotegerin, Dickkopf-related protein 1 (DKK-1), and soluble frizzled-related protein 1 (sFRP-1) were measured in 57 patients with Paget's disease of bone and 24 controls with primary osteoarthritis. Subgroup analysis was employed to identify any differences in bone metabolism biomarker levels according to disease activity or current treatment.Results: Patients with PDB presented higher levels of osteopontin and RANKL. When compared with patients with inactive disease, patients with active disease presented higher levels of bone-specific alkaline phosphatase (BAP) and osteopontin. There was a significant correlation between serum levels of BAP and osteopontin. There was no significant correlation between levels of BAP and other bone metabolism biomarkers. Current disease extension on bone scintigraphy had a significant correlation with serum levels of osteopontin and BAP. There was no significant correlation between current disease extension and other bone metabolism biomarkers. Serum levels of osteopontin and RANKL were correlated to serum levels of BAP and disease extension.Conclusion: Patients with PDB presented higher levels of osteopontin and RANKL. Osteopontin could be a useful biomarker for activity and extension of PDB.